Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
FibroBiologics, Inc. - Common Stock
(NQ:
FBLG
)
0.2981
+0.0381 (+14.65%)
Streaming Delayed Price
Updated: 1:14 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about FibroBiologics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
FibroBiologics CEO Issues Letter to Shareholders
Today 8:30 EST
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
January 06, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
January 05, 2026
FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatments
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
December 31, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
Monday's session: top gainers and losers
↗
December 15, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Which stocks are gapping on Monday?
↗
December 15, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Monday's pre-market session: top gainers and losers
↗
December 15, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
December 10, 2025
Platform Poised to Expand into Joint and Cartilage Repair
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Payoff of Outstanding Debt
November 26, 2025
Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 25, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
Which stocks are experiencing notable movement on Monday?
↗
November 24, 2025
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Top movers in Monday's session
↗
November 24, 2025
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
The market is filled with gapping stocks in Monday's session.
↗
November 24, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 24, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
November 20, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
November 19, 2025
Via
Benzinga
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
November 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 06, 2025
Via
Benzinga
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at Bio-Europe 2025
October 24, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the 2025 ThinkEquity Conference
October 14, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
September 26, 2025
Via
ACCESS Newswire
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
September 23, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
September 12, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
September 11, 2025
Pilot studies underway to advance IND-enabling preclinical development
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
September 10, 2025
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technology
From
FibroBiologics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
